IPOs are exciting events on Wall Street. Before you go after the next IPO though, learn the basics about what happens before the stock is made available. Read More

Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Analyst Articles
High-P/E growth stocks have made remarkable runs, particularly in the last year or two. But with inflation expectations on the rise, investor appetite for value stocks, which historically outperform during inflationary periods, could grow. With that in mind, we take a look at three stocks in the SMid-Cap Value Portfolio… Read More
To be a successful investor, you can't avoid risk altogether. The stock market is indeed risky, but that is not necessarily a bad thing. Read More
We start with a note on New Oriental Education & Technology (NYSE: EDU), which dropped 14% in Wednesday trading. Other Chinese tutoring stocks fell as well. The cause of the drop was the circulation on Chinese social media a short report that educational authorities in Beijing intend to investigate the… Read More
Preferred stocks are a hybrid between bonds and common stocks. They offer investors both high income and capital appreciation potential. Read More
For now we’re holding on Read More
An indispensable fuel source Read More
Let's see how a short straddle and short strangle options trading strategy could work for you under current market conditions. Read More
When you think a stock will make a big move, but you aren't sure if it will be up or down, consider a straddle or strangle strategy. Read More
Since setting all-time highs in the mid-600s in July, Regeneron (NSDQ: REGN) (Growth Portfolio) has significantly underperformed, trailing the S&P by about 45 percentage points. Biotech stocks in general have lagged, but Regeneron has underperformed the biotech ETF IBB, by about 40 percentage points. We’re keeping close tabs on the… Read More